AAV gene therapy is advancing rapidly—but its future may hinge on manufacturing economics, not science. As therapeutic doses climb and programs scale, cost of goods (COG) is emerging as a critical barrier, with plasmid DNA (pDNA) alone accounting for up to 40% of batch costs.

This article reveals how shifting to cell-free dbDNA™ fundamentally reshapes AAV manufacturing, delivering measurable gains in speed, purity, and efficiency. Economic modeling shows up to 22% COG reduction and millions in annual savings at commercial scale. For CSOs and CMC leaders, the implication is clear: DNA input is no longer a tactical choice—it’s strategic.

Download the full article to explore detailed modeling, optimization scenarios, and the long-term impact on gene therapy scalability.